

REMARKS

Claims 1-3, 5-8, 10, 12, and 24 have been allowed, subject to an Ex parte Quayle action entered by the Examiner.

The foregoing amendment to the specification is presented to address the Examiner's objection to the amended paragraph on page 3. In view of this amendment, the Examiner's objection is now moot.

The Examiner's comment regarding Example 53 of WO 97/16452 is noted with appreciation. Independent Claims 1 and 24 have been amended to delete references to R₃ being lower alkyl, which should alleviate the Examiner's concerns.

OTHER MATTERS

A Request for Continued Examination has been filed to permit the Examiner to review and sign off on the Information Disclosure Statement submitted herewith, listing references cited in the parent application.


LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

CONCLUSION

All issues having been addressed, this application is in condition for allowance. The Examiner is requested to contact applicants' representative at the phone number set forth if he would like to discuss any other issues concerning this application.

Respectfully submitted,


CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Box RCE, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on the below date.

Date:

10/17/02



Carol Gulysen

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

VERSION WITH MARKINGS TO SHOW CHANGES MADE OCTOBER 17, 2002


In the Specification:

The paragraph beginning at page 3, line 16, has been amended as follows:

The term "alkyl" as used herein refers to saturated hydrocarbon radicals containing from 1 to 12 carbon atoms, inclusive. Alkyl radicals may be straight or branched. Exemplary alkyl radicals include n-pentyl, n-hexyl, n-octyl, n-dodecyl, 2-dodecyl, [3,5-diethylcyclohexyl, duryl,] and the like. The term "lower alkyl" as used herein refers to straight or branched chain hydrocarbon radicals having from 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, and the like. "Alkoxy" refers to radicals of the formula -OR, where R is alkyl as defined above: "lower alkoxy" refers to alkoxy radicals wherein R is lower alkyl. "Hydroxy-lower alkyl" refers to radicals of the formula HO-R-, where R is lower alkylene of 1 to 8 carbons, and may be straight, branched, or cyclic. "Hydroxy-lower alkoxy" refers to radicals of the formula HO-R-O-, where R is lower alkylene of 1 to 8 carbons, and may be straight[,] or branched[, or cyclic]. "Lower alkoxy-lower alkyl" refers to groups of the formula R_aO-R_b-, where R_a and R_b are each independently lower alkyl.

In the Claims

1. (Twice Amended) A compound of formula 1:



wherein:

R₁ is aryl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100


R₂ is hydroxy, amino, or lower alkoxy;

R₃ is H, [lower alkyl,] lower acyl, lower alkoxy-acyl, or amino-acyl;

R₄ is H or lower alkyl;

and pharmaceutically acceptable salts thereof.

24. (Twice Amended) A pharmaceutical composition, comprising:
a compound of the formula 1:



wherein

R₁ is aryl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R₂ is hydroxy, amino, or lower alkoxy;

R₃ is H, [lower alkyl,] lower acyl, lower alkoxy-acyl, or amino-acyl;

R₄ is H or lower alkyl;

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.